Drug Profile


Alternative Names: GMA-301

Latest Information Update: 31 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gmax Biopharm
  • Class Antihypertensives; Monoclonal antibodies
  • Mechanism of Action Endothelin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Pulmonary arterial hypertension

Most Recent Events

  • 31 Jan 2018 Getagozumab is available for licensing as of 31 Jan 2018.
  • 16 Dec 2017 Phase-I clinical trials in Pulmonary arterial hypertension (In volunteers) in Australia (Parenteral) (ACTRN12618000121268)
  • 16 Dec 2017 Getagozumab receives Orphan Drug status for Pulmonary arterial hypertension in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top